|Bid||91.50 x 800|
|Ask||92.97 x 900|
|Day's Range||92.23 - 94.59|
|52 Week Range||76.41 - 100.15|
|Beta (3Y Monthly)||0.57|
|PE Ratio (TTM)||57.92|
|Earnings Date||Aug 17, 2015 - Aug 21, 2015|
|Forward Dividend & Yield||2.00 (2.19%)|
|1y Target Est||102.10|
DUBLIN - February 20, 2019 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer by its indirectly wholly owned subsidiaries, Medtronic, Inc. ("Medtronic, ...
Higher sales of medical devices used in the treatment of brain and kidney diseases helped Medtronic PLC offset a slowdown in sales of gear for heart conditions in its latest quarter. Shares of Medtronic rose 0.5% after the biggest stand-alone medical-device company by sales reported improved revenue and earnings for its fiscal third quarter ended Jan. 25. Medtronic Chief Executive Omar Ishrak said in an interview that the medical-device market is healthy, and the company’s diversified business model helped it post sales and earnings growth despite downturns in some areas.
Medtronic stock inched closer to a breakout Tuesday after its fiscal third quarter earnings topped expectations, though sales from diabetes products lagged estimates.
The Medtronic earnings report for the company's fiscal third quarter of 2019 is out.Source: Shutterstock Medtronic (NYSE:MDT) reported earnings per share of $1.29 for its fiscal third quarter of the year. This is up from the company's earnings per share of $1.17 from its fiscal third quarter of 2018. It also beat out Wall Street's earnings per share estimate of $1.24 for its fiscal third quarter of 2019.Medtronic earnings for its fiscal third quarter of the year also includes net income of $1.27 billion. This is an increase over the company's net loss of $1.39 billion reported in the same period of the year prior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Medtronic earnings report for the company's fiscal third quarter of 2019 also has operating income coming in at $1.54 billion. The medical device company reported operating income of $1.44 billion in its fiscal third quarter of the previous year.Revenue reported in the Medtronic earnings release for its fiscal third quarter of the year was $7.55 billion. This is better than the company's revenue of $7.37 billion reported during the same time last year. It also comes in above analysts' revenue estimate of $7.52 billion for the period. * 7 Financial Stocks With Accelerating Growth "Revenue outperformance in our Minimally Invasive Therapies and Restorative Therapies Groups, as well as broad strength across Emerging Markets, helped to offset certain market-specific headwinds we faced during the quarter, reflecting the full benefits of our diversification," Omar Ishrak, Chairman and CEO of Medtronic, said in a statement.MDT stock was up slightly as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Hot Stocks Leading the Market's Blitz Higher * 7 Strong Buy Stocks With Over 20% Upside * 5 Growthy Stocks Trading Below 15X Earnings As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Medtronic Earnings: MDT Reports Q3 Earnings Beat appeared first on InvestorPlace.
U.S. stocks struggled for direction on Tuesday as gains in Walmart offset losses in financials, with trade talks between the United States and China in focus. The S&P index recorded 29 new 52-week highs and no new lows, while the Nasdaq recorded 68 new highs and 17 new lows.
The company has been building its minimally invasive and robotic surgery device businesses through acquisitions to make up for slowing growth in its top-earning unit that makes stents and heart pumps. The minimally invasive therapies business, which makes surgical instruments such as those used to treat hernias and kidney disease, brought in revenue of $2.12 billion in the third quarter, above estimates of $2.08 billion.
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
The world's largest big-box retailer outperformed expectations on both its top and bottom lines for fiscal Q4: $1.41 per share surpassed the $1.33 in the Zacks consensus.
Hopes that the two countries will hammer out a deal to end their protracted trade war had helped the S&P 500 and the Nasdaq log their best week in a month on Friday. "We had a fairly good rally on Friday and there is a hint of profit-taking before the resumption of the trade talks," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. The consumer staples sector rose 0.40 percent, the most among the 11 major S&P sectors, helped by a 3.8 percent rise in shares of Walmart Inc.
Medtronic (MDT) gains on strength in the Minimally Invasive Therapies and Restorative Therapies Groups along with solid performance across emerging markets in Q3.
U.S. stocks were set to dip at the open on Tuesday after rallying strongly last week, as investors focused on the latest round of trade talks between the United States and China. Hopes that the two countries will hammer out a deal to end their protracted trade war helped the S&P 500 and the Nasdaq log their best week in a month on Friday. "We had a fairly good rally on Friday and there is a hint of profit-taking before the resumption of the trade talks," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.
shares were up slightly Tuesday after the medical device maker reported third-quarter earnings and revenue ahead of analysts' expectations. "Our organization executed on multiple fronts to deliver a strong quarter for Medtronic," said Omar Ishrak, Medtronic chairman and chief executive officer. Medtronic shares are up about 3.3% year to date and have risen more than 10% over the past 12 months.
Medtronic PLC (MDT) on Tuesday reported fiscal third-quarter net income of $1.27 billion, after reporting a loss in the same period a year earlier. On a per-share basis, the Dublin-based company said it ...
Medtronic PLC reported fiscal third-quarter net income for the quarter to Jan. 25 that fell to $1.27 billion, or 94 cents a share, from $1.59 billion, or $1.17 a share, in the same period a year ago. Excluding non-recurring items, the medical technology company said adjusted earnings per share came to $1.29, above the FactSet consensus of $1.24. revenue rose 2.4% to $7.55 billion, just above the FactSet consensus of $7.53 billion, as U.S. revenue grew 2.3% to $4.00 billion. Non-U.S. developed market revenue rose 0.6% to $2.37 billion, while emerging market revenue increased 6.8% to $1.18 billion. For fiscal 2019, the company raised its adj. EPS outlook to $5.14 to $5.16 from $5.10 to $5.15 and its revenue growth forecast to 5.25% to 5.50% from 5.00% to 5.50%. The stock, which is still inactive in premarket trade, has gained 2.1% over the past three months while the S&P 500 has advanced 3.2%.
February 19, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The system will also provide insights and predictive diagnostics unique to the individual, with a goal of dramatically simplifying diabetes management for the patient. The recent acquisition of Nutrino Health and their expertise in nutrition data science will play a key role in the accelerated development of this breakthrough technology.
Revenue of $7.5 Billion Increased 2.4% Reported; Increased 4.4% Organic GAAP Diluted EPS of $0.94; Non-GAAP Diluted EPS of $1.29 Operating Margin of 20.4% Increased 90 bps; Non-GAAP Operating Margin of ...